Clinical Trials Conditions Law Microdosing 
Cannabis Law Report
JULY 25, 2022
million ($650,000) in funding from New Zealand’s Health Research Council (HRC) to conduct a LSD microdosing trial in patients with Major Depressive Disorder (MDD). The state agency grant funding followed the successful completion of a phase 1 clinical trial in 80 healthy participants.
The Joint Blog
NOVEMBER 15, 2021
While over the last few years, microdosing has become extremely popular, the act of microdosing has been recommended by experts for at least two decades. There are also many different substances that you can microdose, from psilocybin mushrooms to delta-8. In this article, we are going to cover microdose of legal substances.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
DECEMBER 2, 2021
(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.
Cannabis Law Report
JUNE 19, 2022
For example, compounds such as psilocybin, mescaline, ibogaine, and LSD are being evaluated in clinical trials, but the compounds themselves are unpatentable because their existence is well documented in the prior art. Originally Published At Microdose. However, that does not mean that the path to patents is closed off.
Veriheal
MARCH 20, 2023
Using psilocybin in small doses, or microdosing, has been shown to aid in the treatment of various mental health issues, including anxiety, depression, PTSD, and obsessive-compulsive disorder. Instead, it essentially makes arrests for psilocybin the lowest priority for law enforcement. Missouri Rep. Texas This year, Texas Gov.
Canna Law Blog
NOVEMBER 27, 2021
Notwithstanding its dubious distinction as a Schedule I drug, DMT increasingly is the subject of study for its potential efficacy in treating a wide array of mental-health conditions including depression, anxiety, and PTSD. regulators to launch a clinical program to study the use of DMT for the treatment of stroke-related dysfunction.
Cannabis Law Report
FEBRUARY 9, 2022
“It is kind of a landmark moment because Oregon is the very first state to have created such a system of regulation,” said Mason Marks, a member of Oregon’s psilocybin advisory board and a senior fellow on the Project on Psychedelics Law and Regulation at Harvard Law School. Other species might be introduced later.
Expert insights. Personalized for you.
52 
Let's personalize your content